Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis

NCT ID: NCT04995406

Last Updated: 2024-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

722 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-03

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ISIT-TB Prototype is a diagnostic assay based on a transcriptional blood signature suggestive of the detection of Mycobacterium tuberculosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This device will be investigated for use as a screening tool to facilitate diagnosis of ATB in conjunction with risk assessment, clinical context and diagnostic information. Whole blood samples will be collected in Tempus™ Blood RNA Tubes and processed on an automatized platform. The detection of a combination of under or over-expressed selected genes, constituting a transcriptional signature, will allow the characterization of ATB.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TUBERCULOSIS, PULMONARY

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active TB ATB

Participants with active tuberculosis with diagnosis confirmed by GeneXpert and/or culture positivity

ISIT-TB prototype

Intervention Type DIAGNOSTIC_TEST

Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Latent Tuberculosis Infections LTBI

Participants with presumed latent TB infection

ISIT-TB prototype

Intervention Type DIAGNOSTIC_TEST

Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Healthy controls HC

Participants who do not have Active or Latent tuberculosis or other pathologies investigated in this study

ISIT-TB prototype

Intervention Type DIAGNOSTIC_TEST

Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Non-tuberculous symptomatic participants

This cohort refers to participants who are known with chronic respiratory conditions and present with one or more signs and symptoms suggestive of TB, but in whom microbiological testing is negative.

ISIT-TB prototype

Intervention Type DIAGNOSTIC_TEST

Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ISIT-TB prototype

Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptoms suggestive of TB disease: cough for more than two weeks plus at least one of the following: fever, malaise, weight loss, night sweats, haemoptysis, chest pain or loss of appetite.
* Willingness to give consent to take part in the study.
* Aged \>18 years old.
* Healthy control : no history of TB treatment, no respiratory symptoms, no evidence of active infectious disease, no history of close contacts of active pulmonary TB patients.

Exclusion Criteria

* Pregnant woman
* A person who has received treatment for active TB or LTBI in the past 24 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioMérieux

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Keertan Dheda, Pr

Role: PRINCIPAL_INVESTIGATOR

University of Cape Town

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Cape Town Lung Institute

Cape Town, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Africa

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ISIT-TB 001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Innovation in Tuberculosis
NCT04002869 UNKNOWN